David Illson, MD, Ph.D., Memorial Sloan Kettering Cancer Center and a professor of medicine at Weill Cornell Medical College speaks about ASCO 2021 Highlights in Colorectal Cancer and Gastrointestinal Cancer.
Link to Abstract 4000 – ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).
https://meetinglibrary.asco.org/record/195933/abstract
Link to Abstract LBA4001 – Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.
https://meetinglibrary.asco.org/record/195919/abstract
Link to Abstract 4002 – First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.
https://meetinglibrary.asco.org/record/195932/abstract
Link To Abstract 4003 – Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.
https://meetinglibrary.asco.org/record/195939/abstract
Link to Abstract 4004 – Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).
https://meetinglibrary.asco.org/record/195929/abstract
Link to Abstract TPS4161 – A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).
https://meetinglibrary.asco.org/record/201239/abstract
Link to Abstract – Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).
https://meetinglibrary.asco.org/record/195968/abstract
Link to Abstract – A phase III study of comparing FOLFOX+/-bevacizumab with FOLFOX+/-bevacizumab+ high-dose intravenous vitamin C as first-line therapy in patients with advanced colorectal cancer.
https://meetinglibrary.asco.org/record/191807/abstract
Link to Abstract – Duration of FOLFOX adjuvant chemotherapy in high-risk stage II and stage III colon cancer with deficient DNA mismatch repair.